American Funds and T. Rowe Run with the Bulls
Risk-averse funds show they have upside potential, too.
Risk-averse funds show they have upside potential, too.
Shareholders in growth funds from T. Rowe Price and American Funds are having their cake and eating it, too. For the most part, these funds held up much better during the bear market than other growth funds. If you owned them you still lost money, but not nearly as much as the funds offered by the competition.
Now we’ve got a bona fide growth-stock rally and those funds are still in the lead. At the moment, every single T. Rowe growth fund and all of the growth offerings in the American Funds lineup are running ahead of their peer group. That’s a pretty nice feat for relatively risk-averse shops like T. Rowe and American. It can’t seem fair to investors in Federated Large Cap Growth or Janus Twenty , which trailed in the bear market and are behind the curve for the year to date.
Health-care and media stocks have driven T. Rowe Price Mid-Cap Growth (RPMGX)
and T. Rowe Price New America Growth (PRWAX) to gains of more than 20% this year. T. Rowe Price New Horizons (PRNHX) manager has them beat with a 29% year-to-date return thanks to huge gainers like Gilead Sciences (GILD) and Exult . New Horizons is one of T. Rowe's boldest funds, but it, too, held up better than its peers during the sell-off.
At American Funds, the story is media and telecommunications. American Funds New Economy (ANEFX) is up 22% thanks to companies like Yahoo and AT&T Wireless . For the giant Growth Fund of America (AGTHX), media, telecom, and retailers like Target (TGT) and Lowe’s (LOW) have led to a fine 17% gain.
Although American and T. Rowe are a far cry from the hyperaggressive momentum shops that typically lead the way in big growth rallies, they did have a couple of things going for them this time around. First, as I’ve noted, some of the steady-growth companies that these firms favor have been stars of the rally. In addition, they took advantage of the bear market to scoop up fallen growth stocks at cheap prices. Many of T. Rowe’s growth funds did well in the early stages of the growth rally during the 1990s but started to lose ground in 1998 when speculation took hold.
In the unlikely event that the market were to become as speculative and momentum-driven as it was in the late 1990s, I wouldn’t expect American or T. Rowe to continue leading the pack. But that was probably a once-in-a-lifetime event. Historically, the market has been more sporadic than it has over the last decade. One year it’s up, the next year it’s down, and so on. If we do get that type choppy market for the next 10 years, T. Rowe and American ought to work out nicely for shareholders.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.